# Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy

> **NCT00726544** · PHASE2 · TERMINATED · sponsor: **Archemix Corp.** · enrollment: 100 (estimated)

## Conditions studied

- Thrombotic Microangiopathy
- Thrombotic Thrombocytopenic Purpura

## Interventions

- **DRUG:** ARC 1779 Placebo
- **DRUG:** ARC1779 Injection
- **DRUG:** ARC1779 Injection
- **DRUG:** ARC1779 Injection

## Key facts

- **NCT ID:** NCT00726544
- **Lead sponsor:** Archemix Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12
- **Primary completion:** 2010-12
- **Final completion:** 2011-03
- **Target enrollment:** 100 (ESTIMATED)
- **Why stopped:** Enrollment into study was slower than expected.
- **Last updated:** 2009-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00726544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00726544, "Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00726544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*